Torrent Pharmaceuticals Ltd. executives recently commented on their acquisition strategy and expectations even as speculation around deals for Indian companies like JB Chemicals & Pharmaceuticals Ltd. and Bharat Serums And Vaccines Limited (BSV) were doing the rounds, with Torrent also in the mix of rumored bidders.
Torrent On Acquisition And Licensing Strategy, Vonoprazan Trajectory
FY25: 5-10 Product Approvals Expected In US
Amid deals activity in India, Torrent Pharma executives spelt out their acquisition expectations and licensing strategy while an in-licensed Takeda brand did well in Q1 of FY25. The US growth trajectory is seen determined by five to ten product approvals expected this fiscal

More from Strategy
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
More from Business
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.